Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Meir Medical Center |
---|---|
Information provided by: | Meir Medical Center |
ClinicalTrials.gov Identifier: | NCT00716365 |
USF Hemostasis - USage of HemCon for Femoral Hemostasis after Percutaneous Procedures. A Comparative Open Label Study The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.
We hypothesize that the use of HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's satisfaction without increasing vascular complications.
278 patients undergoing diagnostic coronary angiography receiving 2500 u intravenous Heparin will be studied and randomized for manual homeostasis with either a HemCon or a regular pad. Primary efficacy endpoint will be time to hemostasis. Secondary endpoints will be safety (complication rate) and satisfaction of patients regarding time to sitting incline and time to ambulation. 25% of patients from each arm will be randomized for Duplex examination of the femoral artery at the access site.
Condition | Intervention | Phase |
---|---|---|
Coronary Angiography |
Device: HemCon bandage |
Phase IV |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous |
Estimated Enrollment: | 278 |
Study Start Date: | January 2008 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
HemCon: Experimental
The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis. The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's. |
Device: HemCon bandage
5 cm X 5 cm
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Contact: Morris Mosseri, MD | 972-9-747-1587 | morris.mosseri@clalit.org.il |
Contact: Nili Erez | 972-9-747-2900 | erez.nili@clalit.org.il |
Israel | |
Meir Medical Center | Recruiting |
Kfar-Saba, Israel, 44281 |
Principal Investigator: | Morris Mosseri, MD | Tel-Aviv University, Sackler School of Medicine |
Responsible Party: | Division of Cardiology, Meir Medical Center, Kfar-Saba, Israel ( Prof. Morris Mosseri ) |
Study ID Numbers: | 0152-07MMC |
Study First Received: | May 22, 2008 |
Last Updated: | August 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00716365 |
Health Authority: | Israel: Ministry of Health |
angiography hemostasis femoral artery duplex |